Invivyd (NASDAQ:IVVD - Get Free Report) had its price objective decreased by HC Wainwright from $10.00 to $5.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. HC Wainwright's price objective suggests a potential upside of 472.08% from the stock's current price.
Separately, D. Boral Capital reiterated a "buy" rating and issued a $9.00 target price on shares of Invivyd in a report on Friday, May 16th.
View Our Latest Stock Analysis on Invivyd
Invivyd Stock Down 2.8%
Shares of Invivyd stock traded down $0.03 during trading on Wednesday, reaching $0.87. The company's stock had a trading volume of 798,879 shares, compared to its average volume of 4,470,269. The business's 50-day moving average price is $0.63 and its 200-day moving average price is $0.74. The firm has a market cap of $104.85 million, a PE ratio of -0.44 and a beta of 0.40. Invivyd has a 52 week low of $0.35 and a 52 week high of $2.74.
Invivyd (NASDAQ:IVVD - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.10). The business had revenue of $11.30 million for the quarter, compared to analysts' expectations of $34.45 million. Equities analysts predict that Invivyd will post -1.64 earnings per share for the current year.
Institutional Investors Weigh In On Invivyd
Several hedge funds have recently bought and sold shares of IVVD. Nuveen LLC bought a new stake in Invivyd in the first quarter valued at $65,000. Invesco Ltd. increased its holdings in Invivyd by 190.6% during the first quarter. Invesco Ltd. now owns 108,999 shares of the company's stock valued at $66,000 after buying an additional 71,485 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Invivyd in the first quarter worth $66,000. Jane Street Group LLC grew its stake in Invivyd by 290.5% during the fourth quarter. Jane Street Group LLC now owns 117,432 shares of the company's stock valued at $52,000 after acquiring an additional 87,358 shares in the last quarter. Finally, Barclays PLC grew its stake in Invivyd by 7.8% during the fourth quarter. Barclays PLC now owns 127,180 shares of the company's stock valued at $56,000 after acquiring an additional 9,207 shares in the last quarter. 70.36% of the stock is currently owned by institutional investors.
Invivyd Company Profile
(
Get Free Report)
Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Invivyd, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Invivyd wasn't on the list.
While Invivyd currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
